Aequus Pharmaceuticals Inc.
AQSZF
$0.0039
$0.000.00%
| Weiss Ratings | AQSZF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | AQSZF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Very Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | AQSZF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.55 | |||
| Price History | AQSZF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | 0.00% | |||
| 60-Day Total Return | 0.00% | |||
| 90-Day Total Return | -45.07% | |||
| Year to Date Total Return | 0.00% | |||
| 1-Year Total Return | -69.29% | |||
| 2-Year Total Return | -83.75% | |||
| 3-Year Total Return | -93.92% | |||
| 5-Year Total Return | -95.30% | |||
| 52-Week High % Change | -82.63% | |||
| 52-Week Low % Change | 0.00% | |||
| Price | AQSZF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.02 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Dec 18, 2024 | |||
| 52-Week High Price (Date) | Jun 21, 2024 | |||
| Valuation | AQSZF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 463.38K | |||
| Enterprise Value | 5.02M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.01 | |||
| Earnings Per Share Growth | -18.13% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 1.77 | |||
| Price/Book (Q) | -0.11 | |||
| Enterprise Value/Revenue (TTM) | 16.47 | |||
| Price | $0.00 | |||
| Enterprise Value/EBITDA (TTM) | -2.74 | |||
| Enterprise Value/EBIT | -2.73 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | AQSZF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 132.63M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | AQSZF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 604 336 7906 | |||
| Address | 200 Granville Street Vancouver, BC V6C 1S4 | |||
| Website | www.aequuspharma.ca | |||
| Country | Canada | |||
| Year Founded | 2013 | |||
| Profitability | AQSZF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -602.87% | |||
| Profit Margin | -649.02% | |||
| Management Effectiveness | AQSZF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -152.14% | |||
| Return on Equity | -- | |||
| Income Statement | AQSZF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 303.10K | |||
| Total Revenue (TTM) | 303.10K | |||
| Revenue Per Share | $0.00 | |||
| Gross Profit (TTM) | 162.00K | |||
| EBITDA (TTM) | -1.82M | |||
| EBIT (TTM) | -1.83M | |||
| Net Income (TTM) | -1.97M | |||
| Net Income Avl. to Common (TTM) | -1.97M | |||
| Total Revenue Growth (Q YOY) | 987.00% | |||
| Earnings Growth (Q YOY) | 24.78% | |||
| EPS Diluted (TTM) | -0.01 | |||
| EPS Diluted Growth (Q YOY) | 24.44% | |||
| Balance Sheet | AQSZF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 18.80K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 227.00K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -4.60M | |||
| Current Ratio (Q) | 0.047 | |||
| Book Value Per Share (Q) | -$0.03 | |||
| Total Assets (Q) | 635.10K | |||
| Total Current Liabilities (Q) | 4.88M | |||
| Total Debt (Q) | 4.84M | |||
| Total Liabilities (Q) | 5.24M | |||
| Total Common Equity (Q) | -4.60M | |||
| Cash Flow | AQSZF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 1.76M | |||
| Net Change in Cash (TTM) | -62.30K | |||
| Levered Free Cash Flow (TTM) | -1.15M | |||
| Cash from Operations (TTM) | -1.82M | |||
